

5 May 2026

36966 BPA Q1 2026 specialist clotting/bleeding medicines

I would like to request the following information for Q1 2026 (January–March 2026).

Please provide total volume (IU/mg) and, where available, total number of patients treated for the following products:

- NovoSeven (eptacog alfa)
- Cevenfacta (eptacog beta)
- FEIBA (anti-inhibitor coagulant complex)
- Obizur (susoctocog alfa)
- Hemlibra (emicizumab) (*haemophilia A inhibitor patients only*)

Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example:

- haemophilia A with inhibitors
- haemophilia B with inhibitors
- Acquired haemophilia (AHA)
- Glanzmann thrombasthenia
- Factor VII deficiency
- other (please specify)

Partial breakdowns (e.g. for only some indications) are welcome.

If this level of detail is not routinely captured, please provide the data in the closest available format, or without any indication breakdown.

Belfast Trust supply treatment in line with the National Framework and report all diagnosis, treatments and regimes on a quarterly basis to the National Haemophilia Database provided by the UKHCDO. Any individual/company can apply to the National Haemophilia Database for this information.

Under Section 21 of the Freedom of Information Act 2000 (Information accessible to the applicant by other means), Belfast Trust is not required to provide information that is already available from another source.

5 May 2026

Applications for access to this data may be made directly to the National Haemophilia Database, which assesses requests in line with its own governance and disclosure arrangements.

Further information on accessing National Haemophilia Database data can be found via the UKHCDO. For your convenience contact details have been provided below:

UKHCDO, Suite 1, 2nd Floor of Anchorage One
Anchorage Quay
Salford Quays
M50 3YJ
Tel : 0161 850 8102
Email: support@ukhcdo.org

[NHD – UKHCDO](#)